Literature DB >> 25980484

Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study.

Sjoerd J Finnema1,2, Christer Halldin3, Benny Bang-Andersen4, Christoffer Bundgaard4, Lars Farde3,5.   

Abstract

RATIONALE: A number of serotonin receptor positron emission tomography (PET) radioligands have been shown to be sensitive to changes in extracellular serotonin concentration, in a generalization of the well-known dopamine competition model. High doses of selective serotonin reuptake inhibitors (SSRIs) decrease serotonin receptor availability in monkey brain, consistent with increased serotonin concentrations. However, two recent studies on healthy human subjects, using a single, lower and clinically relevant SSRI dose, showed increased cortical serotonin receptor radioligand binding, suggesting potential decreases in serotonin concentration in projection regions when initiating treatment.
OBJECTIVES: The cross-species differential SSRI effect may be partly explained by serotonin transporter (SERT) occupancy in monkey brain being higher than is clinically relevant. We here determine SERT occupancy after single doses of escitalopram or citalopram by conducting PET measurements with [(11)C]MADAM in monkeys. Relationships between dose, plasma concentration and SERT occupancy were estimated by one-site binding analyses. Binding affinity was expressed as dose (ID50) or plasma concentration (K i) where 50 % SERT occupancy was achieved.
RESULTS: Estimated ID50 and K i values were 0.020 mg/kg and 9.6 nmol/L for escitalopram and 0.059 mg/kg and 9.7 nmol/L for citalopram, respectively. Obtained K i values are comparable to values reported in humans.
CONCLUSIONS: Escitalopram or citalopram doses nearly saturated SERT in previous monkey studies which examined serotonin sensitivity of receptor radioligands. PET-measured cross-species differential effects of SSRI on cortical serotonin concentration may thus be related to SSRI dose. Future monkey studies using SSRI doses inducing clinically relevant SERT occupancy may further illuminate the delayed onset of SSRI therapeutic effects.

Entities:  

Keywords:  Citalopram; Non-human primate; Occupancy; PET; Serotonin; Transporter

Mesh:

Substances:

Year:  2015        PMID: 25980484     DOI: 10.1007/s00213-015-3961-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  44 in total

1.  PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram.

Authors:  Johan Lundberg; Jacob Strøyer Christophersen; Kamilla Buchberg Petersen; Henrik Loft; Christer Halldin; Lars Farde
Journal:  Int J Neuropsychopharmacol       Date:  2007-01-04       Impact factor: 5.176

2.  D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.

Authors:  L Farde; F A Wiesel; A L Nordström; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients.

Authors:  Svante Nyberg; Sven-Jonas Dencker; Ulf Malm; Marja-Liisa Dahl; Jan-Olof Svenson; Christer Halldin; Yoshifumi Naskashima; Lars Farde
Journal:  Int J Neuropsychopharmacol       Date:  1998-12       Impact factor: 5.176

4.  Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study.

Authors:  N Bel; F Artigas
Journal:  Eur J Pharmacol       Date:  1992-12-08       Impact factor: 4.432

5.  Pharmacological characterization of N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity.

Authors:  Sylvie Chalon; Jari Tarkiainen; Lucette Garreau; Hakan Hall; Patrick Emond; Johnny Vercouillie; Lars Farde; Philippe Dasse; Katarina Varnas; Jean-Claude Besnard; Christer Halldin; Denis Guilloteau
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

6.  Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

Authors:  Jeffrey H Meyer; Alan A Wilson; Sandra Sagrati; Doug Hussey; Anna Carella; William Z Potter; Nathalie Ginovart; Edgar P Spencer; Andy Cheok; Sylvain Houle
Journal:  Am J Psychiatry       Date:  2004-05       Impact factor: 18.112

7.  Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex.

Authors:  R Invernizzi; S Belli; R Samanin
Journal:  Brain Res       Date:  1992-07-03       Impact factor: 3.252

8.  In vivo evaluation of [¹²³I]mZIENT as a SPECT radioligand for the serotonin transporter.

Authors:  Jeffery Batis; Olivier Barret; David Alagille; Andrei O Koren; Jeffrey S Stehouwer; Kelly Cosgrove; Mark Goodman; John Seibyl; Gilles Tamagnan
Journal:  Nucl Med Biol       Date:  2012-11       Impact factor: 2.408

9.  Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study.

Authors:  S Selvaraj; F Turkheimer; L Rosso; P Faulkner; E Mouchlianitis; J P Roiser; P McGuire; P J Cowen; O Howes
Journal:  Mol Psychiatry       Date:  2012-06-05       Impact factor: 15.992

10.  A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques.

Authors:  H Yamanaka; C Yokoyama; H Mizuma; S Kurai; S J Finnema; C Halldin; H Doi; H Onoe
Journal:  Transl Psychiatry       Date:  2014-01-07       Impact factor: 6.222

View more
  4 in total

1.  Quantification of PET infusion studies without true equilibrium: A tissue clearance correction.

Authors:  Ansel T Hillmer; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2019-05-14       Impact factor: 6.200

2.  Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study.

Authors:  Ansel T Hillmer; David Matuskey; Yiyun Huang; Nabeel Nabulsi; Jim Ropchan; Richard E Carson; Stephanie S O'Malley; Kelly P Cosgrove
Journal:  J Nucl Med       Date:  2020-01-31       Impact factor: 10.057

3.  Potential Effect of Prolonged Sevoflurane Anesthesia on the Kinetics of [11C]Raclopride in Non-human Primates.

Authors:  Ryosuke Arakawa; Lars Farde; Junya Matsumoto; Naoki Kanegawa; Igor Yakushev; Kai-Chun Yang; Akihiro Takano
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

4.  Characterization of [11C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain.

Authors:  Kai-Chun Yang; Vladimir Stepanov; Nahid Amini; Stefan Martinsson; Akihiro Takano; Jacob Nielsen; Christoffer Bundgaard; Benny Bang-Andersen; Sarah Grimwood; Christer Halldin; Lars Farde; Sjoerd J Finnema
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-05       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.